(E907) Lyxor 1 MDAX (DR) I - Ratings and Ratios

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: DE000ETF9074

German Stocks, Small Cap, Equity

Description: E907 Lyxor 1 MDAX (DR) I

The Lyxor 1 MDAX (DR) UCITS ETF I (XETRA:E907) is a small-cap equity ETF designed to track the performance of small-cap companies in Germany. It replicates the MSCI Germany Small Cap NR EUR index, offering investors exposure to a diversified portfolio of German small-cap stocks. The ETF is listed on XETRA and is structured as a UCITS-compliant fund, ensuring transparency and regulatory compliance. It is tailored for investors seeking targeted exposure to the German small-cap market, which may include companies across various sectors such as technology, industrials, and consumer goods.

From a technical perspective, the ETF currently trades at 137.68 EUR, with a 20-day average volume of 2,182 shares. Its short-term trend indicators show the price slightly above the 20-day SMA (137.21) and 50-day SMA (131.97), while it remains below the 200-day SMA (129.38). The ATR of 1.71 indicates moderate price volatility over the past 20 days. These metrics suggest the ETF is in a consolidative phase, with potential resistance at the 200-day SMA level.

Fundamentally, the ETF manages an AUM of 132.51M EUR, reflecting its role as a niche small-cap fund. Its focus on small-cap German equities makes it sensitive to domestic economic conditions, including consumer spending, industrial production, and monetary policy. Investors should consider the ETFs liquidity profile, as small-cap stocks can experience higher volatility and lower trading volumes compared to large-cap counterparts.

Over the next three months, based on , the ETFs price is expected to remain range-bound between 130-140 EUR, influenced by its current SMA levels and ATR. If the price breaks above the 200-day SMA (129.38), it may signal upward momentum, potentially targeting the 140 EUR resistance level. Conversely, a drop below the 50-day SMA (131.97) could indicate downside risk, with support potentially at 125 EUR. suggests the ETFs performance will closely align with Germanys small-cap equity market, which may be impacted by broader economic trends in the Eurozone.

Additional Sources for E907 ETF

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

E907 ETF Overview

Market Cap in USD 155m
Category Germany Small/Mid-Cap Equity
TER 0.30%
IPO / Inception 2015-10-30

E907 ETF Ratings

Growth Rating 3.45
Fundamental -
Dividend Rating 56.7
Rel. Strength -10.4
Analysts -
Fair Price Momentum 146.47 EUR
Fair Price DCF -

E907 Dividends

Dividend Yield 12m 1.72%
Yield on Cost 5y 1.77%
Annual Growth 5y 13.05%
Payout Consistency 90.3%
Payout Ratio %

E907 Growth Ratios

Growth Correlation 3m 65%
Growth Correlation 12m 81.5%
Growth Correlation 5y -53%
CAGR 5y 1.78%
CAGR/Max DD 5y 0.04
Sharpe Ratio 12m 1.73
Alpha 6.21
Beta 0.659
Volatility 14.53%
Current Volume 0.2k
Average Volume 20d 0.4k
Stop Loss 143.9 (-3%)
What is the price of E907 shares?
As of July 15, 2025, the stock is trading at EUR 148.40 with a total of 183 shares traded.
Over the past week, the price has changed by +0.91%, over one month by +2.42%, over three months by +14.26% and over the past year by +15.83%.
Is Lyxor 1 MDAX (DR) I a good stock to buy?
Neither. Based on ValueRay´s Analyses, Lyxor 1 MDAX (DR) I is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 3.45 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of E907 is around 146.47 EUR . This means that E907 is currently overvalued and has a potential downside of -1.3%.
Is E907 a buy, sell or hold?
Lyxor 1 MDAX (DR) I has no consensus analysts rating.
What are the forecasts for E907 share price target?
According to our own proprietary Forecast Model, E907 Lyxor 1 MDAX (DR) I will be worth about 165.2 in July 2026. The stock is currently trading at 148.40. This means that the stock has a potential upside of +11.31%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 165.2 11.3%